A detailed history of Price T Rowe Associates Inc transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 81,500 shares of TGTX stock, worth $2.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
81,500
Previous 87,921 7.3%
Holding current value
$2.62 Million
Previous $1.57 Million 21.85%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$17.21 - $25.28 $110,505 - $162,322
-6,421 Reduced 7.3%
81,500 $1.91 Million
Q2 2024

Aug 14, 2024

BUY
$13.32 - $19.19 $30,875 - $44,482
2,318 Added 2.71%
87,921 $1.57 Million
Q1 2024

May 15, 2024

BUY
$13.02 - $21.3 $65,295 - $106,819
5,015 Added 6.22%
85,603 $1.3 Million
Q4 2023

Feb 14, 2024

BUY
$6.68 - $18.81 $182,023 - $512,553
27,249 Added 51.09%
80,588 $1.38 Million
Q3 2023

Nov 14, 2023

SELL
$8.36 - $26.5 $2.05 Million - $6.48 Million
-244,700 Reduced 82.1%
53,339 $446,000
Q2 2023

Aug 14, 2023

BUY
$15.48 - $35.0 $3.46 Million - $7.82 Million
223,545 Added 300.08%
298,039 $7.4 Million
Q1 2023

May 15, 2023

SELL
$10.23 - $19.34 $185,899 - $351,446
-18,172 Reduced 19.61%
74,494 $1.12 Million
Q4 2022

Feb 14, 2023

SELL
$5.01 - $11.83 $59,704 - $140,978
-11,917 Reduced 11.39%
92,666 $1.1 Million
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $19,769 - $36,338
4,326 Added 4.31%
104,583 $620,000
Q2 2022

Aug 15, 2022

SELL
$3.74 - $10.66 $1.8 Million - $5.12 Million
-480,718 Reduced 82.74%
100,257 $426,000
Q1 2022

May 16, 2022

SELL
$7.81 - $20.45 $132 - $347
-17 Reduced -0.0%
580,975 $5.53 Million
Q4 2021

Feb 14, 2022

SELL
$15.2 - $35.51 $12.8 Million - $30 Million
-844,156 Reduced 59.23%
580,992 $11 Million
Q3 2021

Nov 15, 2021

SELL
$21.78 - $40.45 $9.99 Million - $18.5 Million
-458,503 Reduced 24.34%
1,425,148 $47.4 Million
Q2 2021

Aug 16, 2021

BUY
$32.5 - $48.96 $8.66 Million - $13 Million
266,310 Added 16.47%
1,883,651 $73.1 Million
Q1 2021

May 17, 2021

BUY
$41.61 - $54.3 $9.01 Million - $11.8 Million
216,496 Added 15.45%
1,617,341 $78 Million
Q4 2020

Feb 16, 2021

BUY
$25.27 - $54.9 $35.4 Million - $76.9 Million
1,400,845 New
1,400,845 $72.9 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.68B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.